Cancer Research UK
VC Fund
London, United Kingdom
Cancer Research UK is a VC fund in London focused on Health Care and Biotechnology. Cancer Research UK pioneers life-saving research to bring forward the day when all cancers are cured.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Cancer Research UK invests in
Stages Cancer Research UK invests in
Countries Cancer Research UK invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
Nick Jame
|
|||
| See all 6 contacts → | |||
Investment Focus
Industry
- Health Care 3 (60%)
- Biotechnology 3 (60%)
- Medical 1 (20%)
- Therapeutics 1 (20%)
- Health Diagnostics 1 (20%)
Stage
- Grant 3 (60%)
- Seed 2 (40%)
Country
- United Kingdom 3 (60%)
- Singapore 1 (20%)
- The Netherlands 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Avin Talabani
Emerging Technology Exploration Lead
|
Emerging Technology Exploration Lead | Total investments: 0 | Find email | |
|
James Ritchie
Drug Development Strategy Lead
|
Drug Development Strategy Lead | Total investments: 0 | Find email | |
|
Philip Almond
Executive Director Fundraising & Marketing
|
Executive Director Fundraising & Marketing | Total investments: 0 | Find email | |
|
Dmitry Soloviev
Senior PET chemist, Beatson Institute
|
Senior PET chemist, Beatson Institute | Total investments: 0 | Find email | |
|
Nick Jame
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders. | $13.4M / Seed / Dec 03, 2025 | |
|
|
University of the West of Scotland is a school. | Grant / Mar 21, 2023 | |
|
|
North East Innovation Lab is part of Newcastle Hospitals that helps hospitals in development of new diagnostics. | $265.4K / Grant / Jul 28, 2022 | |
|
|
OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection. | $1.8M / Seed / Sep 06, 2021 | |
|
|
Sengenics is a functional proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded and functional proteins. KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics.The keyapplication of KREX™ is the discovery of autoantibody biomarkers for two core medical use cases. Firstly, stratification of patients undergoing treatment with autoimmune or cancer drugs into responders, non-responders and those that may exhibit severe immune-related adverse events. Secondly, identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. | Grant / Nov 26, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Cancer Research UK invest in?
Cancer Research UK invests primarily in Health Care, Biotechnology and Medical startups, most often at Grant and Seed stage. Most of the 5 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cancer Research UK?
Public channels for Cancer Research UK include X (Twitter), the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cancer Research UK?
The team at Cancer Research UK includes Avin Talabani (Emerging Technology Exploration Lead), James Ritchie (Drug Development Strategy Lead) and Philip Almond (Executive Director Fundraising & Marketing), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!